Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound ... a head-to-head contest with the latter's Wegovy (semaglutide) brand. Both companies have been ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...
"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super Bowl ad, leveling the accusation against brand-name weight loss drugs. Set ...
Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or side effect disclosures. These compounded drugs, unlike generics, are not ...
Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...
For more control, third-party tools like TranslucentTB and TaskbarTools let users make the taskbar fully transparent or adjust its transparency level. These apps are easy to use, lightweight, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results